怀孕期间使用静止剂和先天性缺陷的风险:挪威全国性研究
Jacob J Christensen1, Kirsten B Holven1,2, Martin P Bogsrud3
1Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, Oslo 0317, Norway.
European heart journal
|August 21, 2025
概括
这项研究发现,怀孕期间使用他类药物或脂质修饰剂 (LMA) 与先天性形之间没有显著的联系. 这些发现表明这些药物可能对胎儿的发育是安全的.
科学领域:
- 生殖健康
- 心血管药理学
- 甲状腺学
背景情况:
- 由于安全问题,类药物和LMA在怀孕期间传统上是禁用的.
- 在子宫内暴露于他类药物和LMA的风险的数据有限.
- 需要澄清母亲使用LMA与胎儿后果之间的关联.
研究的目的:
- 检查第一季度的他类药物/LMA暴露与先天性形之间的关联.
- 用当前的研究数据更新2022年的元分析.
- 在人类怀孕期间评估他类药物和LMA暴露的风险.
主要方法:
- 使用挪威国家注册数据 (2005-2018) 孕妇.
- 使用混合效应的后勤回归来评估关联.
- 使用逆变量和随机效应模型进行了元分析.
主要成果:
- 在他类药物暴露和任何重大或轻微的形之间没有显著的关联.
- 没有增加心脏形的风险.
- 更新后的元分析显示,主要或心脏形的风险没有增加 (OR为1.06和1.24).
结论:
- 这项大型研究和元分析没有发现第一季度的他类药物/LMA暴露与先天性形之间有显著的关联.
- 研究结果不支持母亲使用他类药物与出生缺陷之间存在强烈或独立的联系.
- 虽然不能完全排除弱相关性,但目前的证据表明安全性.
相关概念视频
Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Mitral Valve Prolapse III: Nursing Management
36
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
36
Adrenergic Antagonists: ɑ and β-Receptor Blockers
598
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
598
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
430
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
430
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21


